

1 **SARS-CoV-2 Infects Peripheral and Central Neurons of Mice Before Viremia, Facilitated** 2 **by Neuropilin-1**

3 Jonathan D. Joyce^{1,5}, Greyson A. Moore², Poorna Goswami¹, Emma H. Leslie¹, Christopher K.
4 Thompson³, and Andrea S. Bertke^{4,5*}

5 ¹Translational Biology, Medicine, and Health, Virginia Polytechnic Institute & State University,
6 Blacksburg, VA, USA; jjoyce84@vt.edu, ehenry20@vt.edu, poorna08@vt.edu

7 ²Biomedical and Veterinary Science, Virginia Maryland College of Veterinary Medicine, Virginia
8 Polytechnic Institute & State University, Blacksburg, VA, USA; gamoore@vt.edu

9 ³School of Neuroscience, Virginia Polytechnic Institute & State University, Blacksburg, VA, USA;
10 ckt@vt.edu

11 ⁴Population Health Sciences, Virginia Maryland College of Veterinary Medicine, Virginia
12 Polytechnic Institute & State University, Blacksburg, VA, USA; asbertke@vt.edu

13 ⁵Center for Emerging Zoonotic and Arthropod-borne Pathogens, Virginia Polytechnic Institute &
14 State University, Blacksburg, VA, USA

15 * Correspondence: asbertke@vt.edu

16

17 **Abstract**

18 Neurological symptoms are increasingly associated with COVID-19, suggesting that SARS-CoV-
19 2 is neuroinvasive. Although studies have focused on neuroinvasion through infection of olfactory
20 neurons and supporting cells or hematogenous spread, little attention has been paid to the
21 susceptibility of the peripheral nervous system to infection or to alternative routes of neural
22 invasion. We show that neurons in the central and peripheral nervous systems are susceptible to
23 productive infection with SARS-CoV-2. Infection of K18-hACE2 mice, wild-type mice, and primary
24 neuronal cultures demonstrates viral RNA, protein, and infectious virus in peripheral nervous
25 system neurons, spinal cord, specific brain regions, and satellite glial cells. Moreover, we found
26 that SARS-CoV-2 infects neurons at least in part via neuropilin-1. Our data show that SARS-CoV-
27 2 rapidly invades and establishes productive infection in previously unassessed sites in the
28 nervous system via direct invasion of neurons before viremia, which may underlie some cognitive
29 and sensory symptoms associated with COVID-19.

30

31 **Introduction**

32 Up to 80% of people infected with SARS-CoV-2, the virus responsible for coronavirus disease
33 2019 (COVID-19), report neurological symptoms. These symptoms span the central nervous
34 system (CNS; dizziness, headache, cognitive and memory deficits) and peripheral nervous
35 system (PNS-somatic and autonomic systems; impaired taste, smell, sensation, orthostatic
36 intolerance, syncope)¹⁻³. Fatigue, memory issues, “brain fog,” and autonomic dysfunction can
37 persist as part of post-acute sequelae of SARS-CoV-2 infection (“long COVID”)⁴. Detection of
38 virus, viral RNA, and antigen, in cerebrospinal fluid (CSF) and brains of COVID-19 patients
39 indicates SARS-CoV-2 is neuroinvasive, which has been documented for common-cold
40 coronaviruses (HCoV-OC43, HCoV-229E) and epidemic coronaviruses (MERS, SARS)⁵⁻¹³.

41 As anosmia is a primary symptom of COVID-19, studies were previously conducted to assess the
42 possibility of CNS invasion via olfactory sensory neurons (OSNs), using transgenic mice
43 expressing human angiotensin converting enzyme 2 (hACE2), the receptor for SARS-CoV-2¹⁴⁻¹⁶.
44 Since RNA, protein, and virus were detected in OSNs, sustentacular cells, and brain
45 homogenates, little attention has since been paid to alternative routes of neural invasion or to the
46 role of PNS infection. Further, different regions of the brain have only recently come under
47 scrutiny. Given that PNS symptoms are more commonly reported than CNS symptoms among
48 non-hospitalized COVID-19 patients, who constitute the bulk of those infected, study of the
49 susceptibility of the PNS to infection is needed¹⁷.

50 Therefore, we assessed the susceptibility of PNS sensory (dorsal root ganglia-DRG, trigeminal
51 ganglia-TG) and autonomic (superior cervical ganglia-SCG) neurons to infection with SARS-CoV-
52 2 following intranasal inoculation of K18-hACE2 transgenic mice (hACE2 mice), wild-type
53 C57BL/6J mice (WT), and guinea pigs (GPs). We also assessed neuroinvasion of the spinal cord
54 and specific brain regions (olfactory bulb, cortex, hippocampus, brainstem, cerebellum),
55 characterized viral growth kinetics in primary neuronal cultures, and investigated the contribution
56 of neuropilin-1 (NRP-1) to neuronal entry.


57 We show that PNS sensory neurons are susceptible and permissive to productive infection with
58 SARS-CoV-2 but that autonomic neurons, while susceptible to infection, sustain significant
59 cytopathology and do not release infectious virus. Recovery of infectious virus from the TG, which
60 innervates oronasal mucosa and extends central projections into the brainstem, suggests an
61 alternative route of neuroinvasion independent of OSNs. We also show that infectious virus can
62 be recovered from spinal cord and lumbosacral DRGs, which may underlie some sensory
63 disturbances experienced in COVID-19. We further show that SARS-CoV-2 is capable of
64 replicating in specific brain regions, with highest RNA concentrations and viral titers found in the
65 hippocampus, which may contribute to memory disturbances associated with COVID-19.
66 Furthermore, invasion of the brain and PNS occurs rapidly after infection, before viremia,
67 demonstrating direct entry and transport through neurons. Our detection of viral RNA and
68 infectious virus in brains and peripheral ganglia of WT mice demonstrates that neuroinvasion can
69 occur independent of hACE2 and is at least partially dependent on NRP-1. Additionally, we show
70 that GPs are resistant to intranasal SARS-CoV-2 infection.

71 **Results**

72 To assess the susceptibility of PNS and CNS neurons to SARS-CoV-2 infection, we intranasally
73 (IN) inoculated hACE2 mice, WT mice, and GPs with 10^3 PFU (n=12 each) or 10^5 PFU (hACE2
74 n=12-14 each) SARS-CoV-2 USA-WA1/2020 (Extended Data Fig. 1a). Animals were monitored
75 daily and tissues collected three- and six-days post-infection (dpi). Weight loss began after 3 dpi
76 and death occurred at 6 dpi (14%) in hACE2 mice inoculated with 10^5 PFU. All other mice survived
77 (Extended Data Fig. 1b). RT-qPCR showed low-level transient viremia with minimal invasion of
78 the viscera (Extended Data Fig. 2), with highest viral RNA concentrations in lungs. These results
79 are similar to previous studies and demonstrate our successful infection of these mice^{16, 18, 19}.
80 Infected GPs gained weight slower than uninfected controls and had mild increase in temperature
81 without signs of disease (Extended Data Fig. 1b). Viral RNA was not detected in any tissues and
82 no viral antigen was detected in lung or brains by immunostaining for SARS-CoV-2 nucleocapsid
83 (SARS-N) (Extended Data Fig. 3).

84 **PNS sensory TG and sympathetic SCG neurons innervating the oronasopharynx are**
85 **susceptible to infection.** Both sensory and sympathetic pathways through TGs and SCGs,


86 respectively, could serve as neural routes for neuroinvasion. The trigeminal nerve provides
 87 sensory innervation to the nasal septum, as well as oronasal mucosa, and projects into the
 88 brainstem. The SCG provides sympathetic innervation to salivary glands and vasculature of the
 89 head and brain, with preganglionic neurons residing in the spinal cord. To assess susceptibility of
 90 these peripheral neurons to infection with SARS-CoV-2, TGs and SCGs were assessed for viral
 91 RNA, protein, and infectious virus. We detected viral RNA at 3- and 6-dpi in TGs and SCGs in
 92 both inoculum groups in hACE2 and WT mice. Viral RNA concentrations were lower in WT than
 93 hACE2 mice (Fig. 1a-b). RNA concentrations increased over time in TGs and SCGs of hACE2
 94 and WT mice, suggesting genome replication. Immunostaining detected SARS-N in the majority
 95 of TG neurons of hACE2 mice, as well as in $\approx 30\%$ of TG neurons of WT mice (Fig. 1c, Extended
 96 Data Fig. 4). All SCG neurons from hACE2 mice were SARS-N-positive, showing substantial
 97 pathology with vacuolated neurons and loss of ganglionic architecture. Although SCGs from WT
 98 mice remained intact, SARS-N was evident in all neurons and some vacuolization was observed.
 99 Infectious virus was detected in TGs collected 3 dpi (0.5 log PFU/mg homogenate) and 6 dpi (2
 100 log PFU/mg homogenate) from hACE2 mice. Infectious virus was not detected from SCGs.
 101 Considering the pathology of the ganglia, the virus may have produced such significant
 102 cytotoxicity that production of viral progeny was impossible. The use of multiple complementary
 103 assays indicate that viral RNA and protein can be isolated from both TGs and SCGs of both
 104 hACE2 and WT mice, and that infectious virus can be recovered from TGs. These data indicate
 105 that TGs and SCGs are susceptible to infection with SARS-CoV-2, that the TG may serve as a
 106 route of CNS invasion, and that neuroinvasion can occur independent of hACE2. All GPs were
 107 negative for viral RNA.



108

109 **Fig 1. | SARS-CoV-2 infection of TG and SCG in hACE2 and wildtype (WT) mice.** **a**, SARS-CoV-2 RNA
110 was detected at increasing concentration in SCGs of hACE2 and WT mice in both inoculum groups from 3
111 to 6 DPI. The SCG provides sympathetic innervation to the salivary glands and blood vessels of the head,
112 neck, and brain. Three-way ANOVA detected a significant difference ($F(7, 40) = 3.902, P = 0.0025$) in RNA
113 genome copy number. Tukey's honestly significant difference (HSD) post hoc tests detected significant
114 differences between the hACE2 and WT groups inoculated with 10^3 PFU assessed at 3 dpi ($p = 0.0464$) as
115 well as the WT groups inoculated with 10^3 PFU assessed at 3- and 6-dpi ($p = 0.029$). **b**, SARS-CoV-2 RNA
116 was detected at increasing concentration in TGs of hACE2 and WT mice in both inoculum groups from 3
117 to 6 DPI. The TG provides sensory innervation to the face, including the nasal septum, and sends
118 projections to the brain stem, thereby providing an alternative entry point for SARS-CoV-2. No statistically
119 significant differences were detected between the groups ($F(7, 40) = 1.405, P = 0.2305$). **c**,
120 Immunofluorescence for SARS-CoV-2 nucleocapsid (SARS-N, grey) and NeuN (red) labeled neurons in
121 TG and SCG sections. SARS-N is more prevalent in hACE2 than in WT but observable in both. No SARS-
122 N was detected in ganglia from uninfected animals. Neurons in SCG were particularly sensitive to infection;
123 significant vacuolization was observed in infected hACE2 SCG cells, visible in single z-plane. Contrast for
124 NeuN was increased in the z-plane to better illustrate residual NeuN immunoreactivity inside SARS-N-
125 negative vacuoles in the highlighted box above. This cytopathology was common across numerous SCGs
126 in both hACE2 and WT mice. Data are the mean \pm s.e.m. Log transformed RNA genome copy numbers
127 were statistically compared by three-way ANOVA (independent variables: inocula, days post infection,
128 genotype). Pairwise comparisons were conducted using Tukey's HSD post hoc tests. * $p < 0.05$.

129 **PNS sensory DRG and CNS spinal cord neurons are susceptible to infection.** Extending our
130 investigation beyond PNS innervations of the oronasopharynx to other peripheral ganglia, we
131 assessed presence of SARS-CoV-2 RNA, protein, and infectious virus in the DRG. The DRG
132 conveys sensory information (pain, pressure, position) from the periphery and internal organs to
133 the spinal cord. Similar to our results from TGs, the sensory ganglia innervating the head, we
134 detected viral RNA at 3- and 6-dpi in DRGs in both inoculum groups in hACE2 and WT mice (Fig.
135 2a). RNA concentrations increased over time, suggesting genome replication. Immunostaining
136 demonstrated SARS-N in the majority of DRG neurons of hACE2 mice and a small percentage of
137 WT mice (Fig. 2b, Extended Data Fig. 4). Furthermore, SARS-N immunostaining was observed
138 in satellite glial cells in DRG neurons (Fig. 2c, Supplementary Video 1). Infectious SARS-CoV-2
139 was recovered from DRG homogenate of one hACE2 mouse (6 dpi), verifying productive infection
140 (2 PFU/mg homogenate). Presence of viral RNA and infectious virus in neurons with no axonal
141 targets in the head or lungs suggests spread via hematogenous dissemination or via axonal
142 transport from a distal site of infection. Given that DRGs project to the spinal cord, and
143 transmission from the DRG to the cord (or vice versa) is possible, the spinal cord was also
144 assessed. We detected viral RNA at 3- and 6-dpi in both inoculum groups in hACE2 and WT mice
145 (Fig. 2d). We identified punctate SARS-N staining inside spinal cord neurons, as well as diffuse
146 SARS-N signal throughout the spinal cord (Fig. 2e, Extended Data Fig. 5, Supplementary Video
147 2) suggestive of free virus, or at least N protein, in the cord. Infectious virus (4 log PFU/mg
148 homogenate) was recovered from the spinal cord of one hACE2 mouse (6 dpi), demonstrating
149 productive infection. These data further demonstrate that PNS sensory neurons are susceptible
150 to infection with SARS-CoV-2, as are CNS neurons in the spinal cord. All GPs were negative for
151 viral RNA.




152

153 **Fig 2. | SARS-CoV-2 infection of DRG, including satellite glial cells, and lumbosacral spinal cord in**
 154 **hACE2 and WT mice. a,** SARS-CoV-2 RNA was detected in increasing concentrations in DRGs of hACE2
 155 and WT mice in both inoculum groups from 3 to 6 DPI. The DRG conveys sensory information (pain,
 156 pressure, position) from the periphery and organs to the spinal cord. Three-way ANOVA detected a
 157 significant difference ($F(7, 41) = 4.163, P = 0.0015$) in RNA genome copy number. Tukey's HSD detected
 158 differences between the hACE2 and WT groups inoculated with 10^5 PFU at 3 dpi ($p = 0.022$). **b,**
 159 Immunofluorescence for SARS-N (grey) and NeuN (red) in DRG sections from infected and uninfected
 160 hACE2 and WT mice. SARS-N is more prevalent in hACE2 than in WT but observable in both. No SARS-
 161 N was detected in uninfected mice. Detection of RNA and SARS-N in peripheral neurons with no direct
 162 connection to the oronasopharynx suggests spread via hematogenous dissemination or via axonal
 163 transport. **c,** Immunofluorescence for SARS-N (grey) and glutamine synthetase (GS, red) in DRG sections
 164 from infected hACE2 mice. SARS-N was detected in numerous satellite glial cells (GS+) surrounding
 165 infected neurons, indicating neuronal support cells are also susceptible to infection. See Supplementary
 166 Video 1 for 3D rendering of this image. **d,** SARS-CoV-2 RNA was detected in lumbosacral spinal cords of
 167 hACE2 and WT mice in both inoculum groups at both time points. No statistically significant differences
 168 were detected between the groups ($F(7, 25) = 1.3054, P = 0.2885$). **e,** Representative image of
 169 immunofluorescence for SARS-N and NeuN in spinal cord cross-sections from an infected hACE2 mouse
 170 at 6 dpi. SARS-N was observed as discrete puncta (arrowheads in e1 and e2) in neuronal cytoplasm,
 171 reminiscent of viral replication complexes. See Supplementary Video 2 for 3D rendering of this image.
 172 Detection of RNA and SARS-N in the spinal cord demonstrates central neurons are susceptible to infection
 173 and may be infected directly from the DRG, brainstem, or hematogenously. Data are the mean \pm s.e.m.
 174 Log-transformed RNA genome copy numbers were statistically compared by three-way ANOVA
 175 (independent variables: inocula, days post infection, genotype). Pairwise comparisons were conducted
 176 using Tukey's HSD post hoc tests. * $p < 0.05$.

177 **Individual brain regions support varying levels of viral invasion and reproduction.** While
 178 studies have assessed viral RNA and infectious virus in the brain, brain homogenates are typically
 179 tested, which doesn't allow for analysis of spatial differences in the presence of virus in discrete
 180 brain regions and could obscure detection of low levels of RNA or infectious virus in specific
 181 regions^{14, 16, 20-22}. To determine if SARS-CoV-2 is present in specific brain regions, we assessed
 182 the olfactory bulb, hippocampus, cortex, brainstem, and cerebellum for SARS-CoV-2 RNA,
 183 protein, and infectious virus. We detected viral RNA in all brain regions at 3 dpi, which increased
 184 by 6 dpi (Fig. 3a-e), in both hACE2 and WT mice. Higher concentrations of viral RNA were found
 185 in hACE2 mice compared to WT mice in all regions. The highest RNA concentration was detected
 186 in the hippocampus at 6 dpi (Fig. 3b), followed by brainstem, cortex, olfactory bulb, and
 187 cerebellum in hACE2 mice. In WT mice, all regions contained similar quantities of SARS-CoV-2
 188 RNA, suggesting that ACE2-independent spread or replication through the nervous system may
 189 differ compared to hACE2 mice. Infectious virus was recovered from the hippocampus and
 190 brainstem (3 log PFU/mg homogenate) and cortex as early as 3 dpi in hACE2 mice and from all
 191 regions by 6 dpi, with highest concentrations in the hippocampus and cortex (5 log PFU/mg
 192 homogenate) followed by olfactory bulb and brainstem (4 log PFU/mg homogenate) and
 193 cerebellum (2 log PFU/mg homogenate) (Fig. 3f). Unexpectedly, low levels of infectious virus
 194 were recovered from the hippocampi and brainstem of WT mice. These results indicate that viral
 195 invasion and replication is not consistent across the brain and the highest concentrations of virus
 196 are found in areas functionally connected to the olfactory and limbic systems, two systems
 197 strongly impacted during COVID-19. All GPs were negative for viral RNA.

198




199

200 **Fig 3. | SARS-CoV-2 infection of the olfactory bulb and various brain regions in hACE2 and WT mice.**
 201 SARS-CoV-2 RNA was detected in increasing concentration in olfactory bulb **a**, hippocampus **b**, cortex **c**,
 202 brainstem **d**, and cerebellum **e**, of hACE2 and WT mice in both inoculum groups from 3 to 6 DPI. Three-
 203 way ANOVA detected a significant difference ($F(7, 41) = 12.556, P = 0.0001$) in RNA genome copy number
 204 in the olfactory bulb. Tukey's HSD detected differences in the olfactory bulb between hACE2 and WT
 205 groups inoculated with 10^5 PFU assessed at 3 dpi ($p < 0.0001$) as well as between those groups assessed
 206 at 6 dpi ($p = 0.001$). A significant difference ($F(7, 41) = 5.106, P = 0.0003$) was also detected in the
 207 hippocampi of hACE2 mice inoculated with 10^5 PFU assessed at 3- vs 6-dpi ($p = 0.0017$). A significant

208 difference ($F(7, 41) = 6.917, P = <0.0001$) was also detected in the brainstem of the hACE2 and WT groups
209 inoculated with 10^5 PFU assessed at 3 dpi ($p = 0.0103$). While differences were detected in the cortex ($F(7,$
210 $41) = 6.098, P = <0.0001$) and the cerebellum ($F(7, 41) = 6.652, P = <0.0001$) none were between relevant
211 groups. f, Heatmap showing recovery of infectious SARS-CoV-2 from homogenates of the olfactory bulb
212 and specific brain regions assessed for viral RNA. Recovery of infectious virus varied across individual
213 animals with some having no regions with recoverable virus and some with virus in all regions. Of note,
214 infectious virus was recovered from the hippocampi and brainstem of some WT mice, which are regions
215 impacted in COVID-19 disease. Data are the mean \pm s.e.m. Log transformed RNA genome copy numbers
216 were statistically compared by three-way ANOVA (independent variables: inocula, days post infection,
217 genotype). Pairwise comparisons were conducted using Tukey's HSD post hoc tests. * $p < 0.05$, ** $p < 0.01$,
218 *** $p < 0.001$.


219 To further assess localization of SARS-CoV-2 in brain regions, we immunostained sagittal
220 sections of hACE2 brains for SARS-N and neuronal marker NeuN (Fig. 4, Extended Data Fig. 5).
221 At 6 dpi, minimal SARS-N was found in the striatum, geniculate nucleus, superior colliculus,
222 superior olive or cerebellum. In other regions, including frontal cortex, lateral preoptic area and
223 visual cortex, thalamus and nucleus accumbens, the majority of neurons were positive. Some of
224 these regions also showed diffuse SARS-N in tissue (cortex, reticular formation), suggesting
225 differences in pathology within various brain regions. As the reticular formation facilitates motor
226 activity associated with the vagus nerve, pathology in this region would correlate with vagus nerve
227 dysfunction, which is associated with even mild COVID-19 cases²³. Despite finding $>10^4$ copies
228 of viral RNA in the olfactory bulb of all six hACE2 mice, infectious virus was recovered from only
229 one of three mice and SARS-N was absent in the caudal olfactory bulb in assessed mice.
230 However, axons of neurons with cytoplasmic N protein in the olfactory tubercle stained positive
231 for SARS-N, suggesting axonal spread from the olfactory bulb into the olfactory tubercle, where
232 productive infection ensues.

233 In the hippocampus (Fig. 5), neurons with cytoplasmic and axonal SARS-N were evident in the
234 majority of CA1 and CA3 neurons, which receive input from the olfactory system through the
235 entorhinal cortex, supporting axonal spread to the hippocampus. In contrast, the dentate gyrus
236 had few SARS-N positive neurons.



237

238 **Fig 4. | Immunofluorescence for SARS-N (grey) and NeuN (red) in a parasagittal brain section from**
239 **an infected hACE2 mouse assessed 6 DPI.** SARS-N+ neurons were observed throughout multiple brain
240 regions with some notable exceptions. Few SARS-N+ cells were detected in the granule cell layer of the
241 olfactory bulb, the medium spiny neurons in the striatum, and the granule cells in the cerebellum. Relatively
242 few SARS-N+ neurons were identified in the lateral geniculate nucleus, layers 2 and 3 of the visual cortex,
243 and in the superior colliculus. This stood in contrast to adjacent non-visual areas (thalamus, somatosensory
244 cortex, inferior colliculus), which had numerous SARS-N+ neurons. The fact that some of these areas
245 contain GABAergic neurons suggests that inhibitory neurons may be spared infection, at least at this time
246 point.



247


248 **Fig 5. | Immunofluorescence for SARS-N (grey) and NeuN (red) in the hippocampus from an infected**
249 **hACE2 mouse assessed 6 DPI.** SARS-N+ neurons were observed in CA3 and CA1. Very few SARS-N+
250 neurons were detected in the granule cell layer of the dentate gyrus. Of note are SARS-N+ processes in
251 infected neurons throughout the hippocampus, as seen in the magnified regions in lower panels.

252 **SARS-CoV-2 productively infects primary cultured sensory but not autonomic neurons**
253 **from adult mice.** To confirm that PNS sensory and autonomic neurons are both susceptible and
254 permissive to infection with SARS-CoV-2, resulting in release of infectious virus, and to establish
255 basic replication kinetics of SARS-CoV-2 in neurons, DRGs, TGs, and SCGs were infected *ex-*
256 *vivo*. Neurons were harvested from 8-10-week-old hACE2 and WT mice to establish primary
257 neuronal cultures, which were then infected. Media and cells were analyzed separately for viral
258 RNA (RT-qPCR) and infectious virus (plaque assay) to differentiate between intracellular
259 replication and release of infectious virus. Viral RNA levels increased in SCG neurons between
260 2- and 3-dpi, although no increase in viral RNA was detected in media (Fig 6a). Infectious virus
261 wasn't detected in the cellular or media fractions (Fig 6b). These data show that while viral
262 genome replication occurs in SCGs, infectious virus is not released, suggesting abortive infection
263 in sympathetic autonomic neurons. Considering the pathology of the SCGs *in vivo*, SARS-CoV-2
264 appears to be cytotoxic to SCG neurons prior to production of viral progeny. Viral RNA levels
265 increased in TG neurons between 1- and 2-dpi, subsequently falling at 3 dpi (Fig 6a). Infectious
266 virus was recovered from neurons and media from 2- to 4-dpi, declining at 5 dpi in both (Fig 6b),

267 indicating that in TG neurons, genome replication peaks at ~48 hpi, after which infectious virus is
 268 released. While DRGs follow a similar pattern, viral RNA levels exhibited a cyclical pattern with
 269 peaks occurring ~48 h intervals at 2- and 4-dpi (Fig 6a). Infectious virus was recovered from
 270 neurons and media in a similar fashion (Fig 6b). These data indicate successive rounds of
 271 genome amplification and infectious virus release occurs in DRGs, either within individual neurons
 272 without killing them or in additional neurons through a second infection cycle. Taken together,
 273 these data show that PNS sensory neurons are both susceptible and permissive to SARS-CoV-
 274 2 infection resulting in release of infectious virus. Also, they show that while autonomic neurons
 275 are susceptible to infection with SARS-CoV-2 and genome replication can occur, they are not
 276 permissive to release of infectious virus. In parallel, primary neuronal cultures were infected and
 277 fixed at 1, 2, and 3-dpi for immunostaining, which showed few DRG neurons (<5%,) in any culture
 278 became productively infected (Fig 6d), which is reflected in the modest increase in viral RNA and
 279 infectious virus (Fig 6a,b, Extended Data Fig. 6). In addition to genome replication, SCG neurons
 280 were permissive for N protein expression, shown by a positive immunofluorescence signal 1 dpi,
 281 while activated satellite glial cells accompanied dying neurons by 3 dpi (Fig 6c). In TG and DRG
 282 neurons, several phenotypes were observed, including perinuclear SARS-N staining at 1 dpi and
 283 punctate staining in the cytoplasm of enlarged neurons at 3 dpi, likely representing replication
 284 compartments (Fig 6c, Supplementary Video 3-4). Infected sensory neurons showed a variety of
 285 phenotypes, including loss of membrane integrity, cytoplasmic puncta, and seemingly healthy
 286 neurons strongly expressing SARS-N (Fig. 7 inset 1,2). Infected satellite glial cells, which
 287 appeared to be activated, were also present in some primary neuronal cultures (Fig. 7 inset 3).

288 Infection of WT neurons (Fig. 6a,b) showed viral RNA concentrations increased from 1-2 dpi in
 289 SCGs and increases in media at 2- and 4-dpi, similar to hACE2 neurons. Low levels of infectious
 290 virus were recovered in neurons and media at 1 dpi. In TGs, viral RNA concentrations cyclically
 291 peaked at 2- and 5-dpi with minimal increase in media, similar to hACE2 neurons. Low levels of
 292 infectious virus were recovered in neurons and media 1-2 dpi. Viral RNA concentrations in DRGs
 293 steadily increased from 1-4 dpi reaching similar levels to viral RNA concentrations in hACE2
 294 DRGs at 4 dpi, with a concomitant increase in media. Low levels of infectious virus were recovered
 295 in media from 1-2 dpi but a second release, as from hACE2 neurons, was not apparent. These
 296 data show invasion and replication in neurons lacking hACE2, although reduced compared to
 297 hACE2-expressing neurons.


298



299

300 **Fig 6. | SARS-CoV-2 infection of primary neuronal cultures from SCG, TG, DRG of hACE2 and WT**
 301 **mice. a, SARS-CoV-2 RNA was quantified by RT-qPCR separately in SCG, TG, and DRG neurons and**
 302 **media to generate a 4–5-day viral genome replication profile in neurons from hACE2 and WT mice. Viral**

303 genome replication occurs in all neurons following similar patterns with differential infectious virus release
304 into media. Intracellular replication patterns are similar between hACE2 and WT neurons, although at
305 reduced levels in WT neurons. hACE2 DRGs have peaks in genome replication ~48 hpi and ~96 hpi
306 indicating successive rounds of replication. **b**, Infectious virus was quantified by plaque assay on Vero E6
307 cells in SCG, TG, and DRG neuronal cultures to generate growth curves in primary neurons from hACE2
308 and WT mice. Infectious virus was not recovered from SCG neurons indicating abortive infection, likely
309 mediated by cytotoxicity. Infectious virus was recovered from TG and DRG neurons indicating productive
310 infection of these neurons. **c**, Immunofluorescence for SARS-N (grey) and either tyrosine hydroxylase (TH)
311 or Isolectin-B4 (IB4) to counterstain neurons, or glutamine synthase (GS) to stain satellite glial cells. SARS-
312 N was observed in neurons from each of the ganglia. Infected neurons were largely free of neurites by 1
313 dpi. At 3 dpi, many infected neurons exhibited cytopathologies such as degraded neurites, enlarged multi-
314 nucleated cell bodies (arrow) compared to uninfected neurons (arrowhead), and SARS-N+ puncta
315 reminiscent of viral replication compartments. See Supplementary Video 3 for 3D rendering of DRG at 3
316 dpi. See Supplementary Video 4 for 3D rendering of TG at 2 dpi. **d**, The percentage of hACE2 autonomic
317 (SCG) and sensory (DRG) neurons positive for SARS-N were counted from 1-3 dpi. A small percentage of
318 autonomic (SCG) neurons were visibly infected, with significant observable cell death, similar to *in vivo*
319 observations. Infection in sensory (DRG) neurons were consistent from 1-3 dpi, with ~5% infected. Infection
320 of *ex vivo* neurons is less efficient than *in vivo* infection. Scale bar = 20 μ m. Data are the mean \pm s.e.m




321
322 **Fig 7. | SARS-CoV-2 infection of primary DRG neuronal cultures 3 DPI.** Immunofluorescence for SARS-
323 N (grey) and Isolectin-B4 (IB4) to counterstain neurons shows a variety of phenotypes of infected cells,
324 including neurons with a loss of membrane integrity (1), SARS-N+ puncta within and surrounding neurons

325 (2), and seemingly healthy neurons with extensive neurites with strong SARS-N+ staining (arrow in 3).
 326 Infected satellite glial cells were also observed (arrowheads in 3); many appeared to be activated, noted by
 327 the presence of extended cellular processes. These findings are similar to immunostaining of DRGs *in vivo*,
 328 which also contained numerous infected satellite glial cells.

329 **Neuroinvasion of the PNS and CNS occurs before viremia and involves neuropilin-1.** To
 330 determine if neuroinvasion is driven by hematogenous entry or direct neuronal entry, PNS and
 331 CNS tissues were assessed 18 hpi and 42 hpi after intranasal inoculation of hACE2 and WT mice
 332 (Fig. 8a,b). Although no viral RNA was detected in blood at 18 hpi, viral RNA was detected in all
 333 PNS and CNS tissues and salivary glands (innervated by the SCG), with the exception of spinal
 334 cord and cerebellum of WT mice. By 42 hpi, viral RNA was detected in blood in a single hACE2
 335 mouse and had increased in all hACE2 PNS and CNS tissues except SCG. In WT mice, viral
 336 RNA was no longer detected in salivary glands, SCG, or DRG but had increased in brainstem
 337 and hippocampus. Immunostaining did not detect SARS-N in any tissues, indicating that the virus
 338 was transiting through PNS tissues when collected but had not yet begun replication, which
 339 occurs later during infection. These data demonstrate that neuroinvasion occurs rapidly after
 340 infection, is mediated by invasion of and transport along neurons, and can occur independent of
 341 hACE2.

342 Since our WT mice were infected despite absence of hACE2, we investigated the contribution of
 343 neuropilin-1 (NRP-1) to neuronal entry in sensory neurons. NRP-1 has been shown to interact
 344 with SARS-CoV-2 spike, thereby enhancing viral binding and entry in non-neuronal cells²⁴⁻²⁶.
 345 Presence of NRP-1 was confirmed on DRG neurons and satellite glial cells via immunostaining
 346 (Fig. 8c). Primary cultured DRG neurons from hACE2 and WT mice were pretreated with
 347 EG00229, a selective NRP-1 antagonist, infected with SARS-CoV-2, and viral RNA
 348 concentrations were assessed 2 dpi. Viral RNA concentrations were significantly reduced by
 349 99.8% in hACE2 neurons ($p=0.0081$) and 86.7% in WT neurons ($p=0.0141$) (Fig. 8d), indicating
 350 that NRP-1 is a SARS-CoV-2 co-receptor in neurons irrespective of hACE2 expression.



351

352 **Fig 8. | Pre-viremic neuroinvasion of SARS-CoV-2 into PNS and CNS and the role of NRP-1 during**
353 **neuronal entry. a,** Although no viral RNA was detected in blood, low levels of SARS-CoV-2 RNA were
354 detected in PNS and CNS of both hACE2 and WT mice as early as 18 hpi. CNS invasion in hACE2 and
355 WT mice was common in olfactory bulb, hippocampus, cortex, and brainstem. Viral RNA was detected in
356 PNS ganglia and the tissues they innervate (SCG-salivary gland, TG-brainstem) in both hACE2 and WT
357 mice. Viral RNA was detected separately in the DRGs and spinal cords of some mice. By 42 hpi, viral RNA
358 was detected in only one hACE2 mouse, but had increased in brainstem, TG and olfactory bulb, indicating
359 replication in these tissues. **b,** Heatmaps visually displaying RT-qPCR values from panel a. Neuroinvasion
360 in both PNS and CNS occurs rapidly before detectable viremia, thereby indicating direct neural entry and
361 trans-synaptic spread of SARSs-CoV-2. Detection of viral RNA in the DRGs but not the spinal cord in some
362 mice and vice versa in others indicates separate entry routes exist for the DRG and spinal cord. Invasion
363 of the cord likely occurs from the brainstem, as all mice with early spinal cord infection also had brainstem
364 infection. Invasion of the DRG may occur from the periphery. **c,** The transmembrane glycoprotein
365 neuropilin-1 (NRP-1, red), shown to increase SARS-CoV-2 entry into non-neuronal cells, is expressed in
366 neurons and satellite glial cells and was visualized by immunostaining. **d,** Treatment of hACE2 and WT
367 DRG neurons with the NRP-1 antagonist EG00229 prior to infection with SARS-CoV-2 significantly reduced
368 viral RNA concentrations at 2 dpi, the initial peak of viral replication in hACE2 DRG neurons, by 99.8%
369 ($p=0.0081$) in hACE2 neurons and 86.7% ($p=0.0141$) in WT neurons. Thus, NRP-1 is a critical co-receptor
370 mediating viral entry into neurons expressing hACE2 and also enhances viral entry into WT neurons. These
371 data also indicate that that additional host proteins are involved in neuronal entry. Scale bar = 20 μ m. Data
372 are the mean \pm s.e.m.

373

374 Discussion

375 Neurotropic viruses can enter the nervous system hematogenously or through neural pathways.
376 From blood, viruses can infect endothelial cells, gaining access to underlying tissues through lytic
377 destruction of vasculature, or can be transported across the vasculature inside extravasating
378 leukocytes. Viruses can enter neural pathways through peripheral sensory, autonomic, and/or
379 motor axon terminals and transport retrograde toward the CNS, often moving trans-synaptically
380 along functionally connected pathways. SARS-CoV-2 likely uses both mechanisms. SARS-CoV-
381 2 CNS invasion has been proposed via infection of the nasal neuroepithelium with invasion of
382 OSNs, the olfactory bulb, and its cortical projections^{14-16, 18, 20-22}. Organoid, stem cell, microfluidic,
383 and mouse models, correlating with human autopsy findings, demonstrate disruption of
384 endothelial barriers and choroid plexus integrity, as well as transcytosis of SARS-CoV-2,
385 supporting hematogenous CNS entry^{5, 18, 27-31}. While OSNs are a key constituent of the nasal
386 neuroepithelium, the oronasopharynx is innervated by other sensory and autonomic pathways
387 through which SARS-CoV-2 may enter the nervous system. Utilizing hACE2 mice, WT mice, and
388 primary neuronal cultures, we show susceptibility of peripheral neurons to SARS-CoV-2 infection,
389 demonstrating differential replication kinetics and cytopathic outcomes following infection of
390 sensory, autonomic, and central neurons. We also show evidence supporting axonal transport of
391 SARS-CoV-2 and CNS entry, preceding viremia, through neural pathways that functionally
392 connect to brain regions responsible for memory and cognition, which are affected in COVID-19.
393 Furthermore, we show that SARS-CoV-2 can use NRP-1 for neuronal entry in the absence of
394 hACE2 expression. As COVID-19 neurological symptoms are often related to peripheral neuron
395 dysfunction rather than exclusive to CNS symptoms, focusing solely on CNS neuroinvasion takes
396 a myopic view of the potential impacts of SARS-CoV-2 in the PNS.

397

398 Our detection of SARS-CoV-2 in the TG and SCG makes anatomical sense given their innervation
399 of the oronasal mucosa and glands. Viral RNA concentrations were similar in the TG, SCG and
400 olfactory bulb 18 hpi, indicating sensory and autonomic pathways are as susceptible to invasion

401 as the olfactory system. Although few autopsy studies have included the TG, our results
402 complement findings of viral RNA, axonal damage, and neuron loss in the TGs of COVID-19
403 patients^{31, 32}. While viral RNA and protein have been detected in salivary glands of COVID-19
404 patients, and infectious virus has been recovered from saliva, no assessments have been made
405 of the SCG in human autopsies³³⁻³⁶. Within the oronasopharynx, the SCG provides sympathetic
406 nervous system innervation to the oronasal mucosa, salivary glands, and vasculature and would
407 be a logical point for neuroinvasion. Our combined use of *in vivo* and *ex vivo* infections
408 demonstrates that sensory trigeminal neurons are both susceptible and permissive to productive
409 infection with SARS-CoV-2, culminating in release of infectious virus. Isolation of infectious virus
410 from the TG has yet to be reported and further supports the hypothesis that the TG can serve as
411 an alternative route for CNS invasion. Increasing reports of acute necrotizing hemorrhagic
412 encephalopathy (AHNE) associated with COVID-19, often involving the medial temporal lobe,
413 suggest that neuroinvasion may follow a similar pathway as other neurotropic viruses (HSV-1),
414 which causes a nearly identical complication when it reaches the CNS from the TG. Invasion of
415 the brainstem along projections of the TG could damage nuclei important in cardiorespiratory
416 regulation, a feature of severe COVID-19, and at least one imaging study of a COVID-19 patient
417 with AHNE suggested invasion of the brainstem via the TG⁷. The SCG may be of less concern
418 for direct CNS invasion as our neuronal culture infection data indicate abortive infection. However,
419 the pathology of the SCG following infection *in vivo* suggests that SARS-CoV-2 causes
420 substantial, and perhaps irreparable, damage to sympathetic neurons. Although we did not
421 examine thoracic ganglia or the sympathetic trunk, the cytopathology in the SCG has broader
422 implications for cardiac function, which relies on autonomic regulation. It is notable that
423 comparable viral RNA concentrations were detected in TGs and SCGs of WT mice, indicating
424 that both tissues are equally susceptible to infection in the absence of hACE2.

425
426 While entry into the TG and SCG following intranasal inoculation was not unexpected, detection
427 of SARS-CoV-2 in the DRG was. We detected viral RNA in the DRG at levels comparable to the
428 TG, demonstrating that sensory neurons, despite their location, are equally susceptible to
429 infection. How the virus reached such distal peripheral ganglia is uncertain. Given that viral RNA
430 was detected in DRGs 18 hpi, preceding viremia, hematogenous spread is unlikely. Alternatively,
431 retrograde axonal transport into the neuronal cell bodies within the ganglion could occur through
432 central spinal cord projections or from peripheral targets. It is noteworthy that none of the mice
433 with viral RNA in the DRG 18 hpi had RNA in the spinal cord and none with viral RNA in the cord
434 had RNA in the DRG. However, virus was detected in both DRG and spinal cord by 3 dpi. All mice
435 with early spinal cord infection also had brainstem infection. Thus, entry into spinal cord appears
436 to follow CNS invasion at the brainstem but infection of DRG neurons is possible from either
437 central or peripheral axon terminals. Once in the DRG, results from our primary neuronal cultures
438 indicate that viral replication and release of infectious virus occurs cyclically every 48 h. As the
439 virus infected a small percentage of sensory neurons in culture, this pattern likely represents two
440 distinct cycles of productive infection. *In vivo*, however, the majority of DRG neurons were positive
441 for SARS-N, suggesting that infection of sensory neurons within the host is more efficient than *ex*
442 *vivo* infection of cultured neurons. Although COVID-19 symptoms can include tingling, numbness
443 and burning in fingers and toes, which are indicative of nociceptor damage or dysfunction, DRG
444 neurons have yet to be assessed for their susceptibility to infection with SARS-CoV-2, either in
445 animal models or in human autopsies. However, ACE2 is expressed by a subset of nociceptors
446 in human DRGs, particularly in lumbosacral ganglia³⁷. Similarly, no systematic analyses of spinal
447 cords have been conducted, although spinal cord involvement is becoming increasingly
448 associated with COVID-19. A recent review of disorders of the spinal cord in COVID-19 posited
449 that direct invasion of the cord by SARS-CoV-2 could cause these pathologies³⁸. Our results

450 indicate that neurons in the spinal cord and in the DRG are susceptible to SARS-CoV-2 infection
451 and provide a rationale for a deeper investigation of the DRG as a site of productive viral infection
452 in COVID-19, as well as the possibility and direction of axonal transport, since infection of the
453 DRGs may contribute to some sensory disturbances suffered by COVID-19 patients.

454 Our detection of viral RNA and infectious virus in specific brain regions is more granular than what
455 has been previously reported and shows the hippocampus, cortex, and brainstem are all rapidly
456 invaded by SARS-CoV-2 through neural pathways before viremia. TG neurons, with axonal
457 projections to both oronasal epithelium and brainstem, or SCG neurons, with synaptic connectivity
458 to salivary glands and brainstem, could deliver virus directly to the CNS. Viral RNA and protein
459 have been detected in the olfactory bulb, brainstem, cerebellum, and cortex of COVID-19
460 patients^{6, 39, 40}. Our results indicate that viral penetration and replication within the brain is
461 dependent on the region assessed, which suggests the presence of factors (cell types, synaptic
462 connections, vascularization level) that favor invasion and replication in some regions over others.
463 Our detection of infectious virus in the hippocampi and brainstems of both WT and hACE2 mice
464 further underscore the importance of these structures in COVID-19 pathology. Interestingly, there
465 were substantially fewer infected cells in some aspects of the nervous system, which might be
466 due to the particular time point assessed or to the types of neurons present in these areas.
467 Notably, SARS-CoV-2 was detected in CNS and PNS of both hACE2 and WT mice, indicating
468 that hACE2 expression is not a requirement for neuronal infection. We demonstrate that NRP-1,
469 which was shown previously to mediate entry into non-neuronal cells, also mediates entry into
470 neurons. Our inhibition of NRP-1 in cultured DRG neurons from hACE2 mice reduced infection to
471 a greater extent than in neurons from WT mice, indicating that NRP-1 can serve as a co-receptor
472 to enhance infection in the presence of hACE2 expression or an alternative receptor independent
473 of hACE2.

474 Since GPs were used as an animal model for SARS-CoV-1, we also assessed their potential as
475 a model for SARS-CoV-2^{41, 42}. Contrary to previous studies using intraperitoneal inoculation, we
476 show that GPs are resistant to intranasal infection, having no detectable viral RNA in any tissues
477 tested and no SARS-N in lungs or brains. A previous study showed that SARS-CoV-1 did not
478 efficiently infect transfected cells expressing gpACE2⁴³ and recent *in silico* modeling of SARS-
479 CoV-2 spike protein and gpACE2 binding showed altered kinetics, which was believed to limit
480 infectability^{44, 45}. Our results provide direct *in vivo* confirmation, resolving the question of the
481 susceptibility of GPs to infection with SARS-CoV-2 following intranasal inoculation.

482 The extent of both acute and long-term neurological impacts of SARS-CoV-2 are only beginning
483 to be realized. The existence of sensory and autonomic disorders, lasting months beyond initial
484 infection, necessitates a better understanding of the impact of SARS-CoV-2 on the entirety of the
485 nervous system, not just the brain. No studies have assessed the susceptibility of TG or SCG
486 neurons to productive infection by SARS-CoV-2 or to investigate their role in viral invasion of the
487 CNS. Additionally, no studies have determined if distal sensory ganglia such as the DRG can
488 support infection, let alone provide an avenue of infection to the spine. Our work expands what is
489 known about the neuroinvasive potential of SARS-CoV-2 by showing that PNS sensory and
490 autonomic neurons, supporting satellite glial cells, and CNS neurons in the spinal cord are all
491 susceptible to, and in most cases permissive to, productive infection with SARS-CoV-2 via direct
492 neural invasion rather than hematogenous spread. Presence of infectious virus in these tissues
493 shows that routes of neuroinvasion exist beyond OSNs and that invasion can occur independent
494 of ACE2 using NRP-1 as a co-receptor. Our findings support the need to investigate these sites
495 of neuroinvasion to a greater depth than currently exists.

496

497 **Online content statement**

498 Any methods, additional references, Nature Research reporting summaries, source data,
499 extended data, supplementary information, acknowledgements, peer review information; details
500 of author contributions and competing interests; and statements of data and code availability are
501 available at ____.

502 **Main Text References**

- 503 1. Shouman, K., *et al.* Autonomic dysfunction following COVID-19 infection: an early
504 experience. *Clin Auton Res* **31**, 385-394 (2021).
- 505 2. Chou, S.H., *et al.* Global Incidence of Neurological Manifestations Among Patients
506 Hospitalized With COVID-19-A Report for the GCS-NeuroCOVID Consortium and the ENERGY
507 Consortium. *JAMA Netw Open* **4**, e2112131 (2021).
- 508 3. Mao, L., *et al.* Neurologic Manifestations of Hospitalized Patients With Coronavirus
509 Disease 2019 in Wuhan, China. *JAMA Neurol* **77**, 683-690 (2020).
- 510 4. Yang, A.C., *et al.* Dysregulation of brain and choroid plexus cell types in severe COVID-
511 19. *Nature* **595**, 565-571 (2021).
- 512 5. Paniz-Mondolfi, A., *et al.* Central nervous system involvement by severe acute respiratory
513 syndrome coronavirus-2 (SARS-CoV-2). *J Med Virol* **92**, 699-702 (2020).
- 514 6. Puelles, V.G., *et al.* Multiorgan and Renal Tropism of SARS-CoV-2. *N Engl J Med* **383**,
515 590-592 (2020).
- 516 7. Virhammar, J., *et al.* Acute necrotizing encephalopathy with SARS-CoV-2 RNA confirmed
517 in cerebrospinal fluid. *Neurology* **95**, 445-449 (2020).
- 518 8. Xiang, P., *et al.* Case Report: Identification of SARS-CoV-2 in Cerebrospinal Fluid by
519 Ultrahigh-Depth Sequencing in a Patient With Coronavirus Disease 2019 and Neurological
520 Dysfunction. *Front Med (Lausanne)* **8**, 629828 (2021).
- 521 9. Bonavia, A., Arbour, N., Yong, V.W. & Talbot, P.J. Infection of primary cultures of human
522 neural cells by human coronaviruses 229E and OC43. *J Virol* **71**, 800-806 (1997).
- 523 10. Arbour, N. & Talbot, P.J. Persistent infection of neural cell lines by human coronaviruses.
524 *Adv Exp Med Biol* **440**, 575-581 (1998).
- 525 11. Arbour, N., Day, R., Newcombe, J. & Talbot, P.J. Neuroinvasion by human respiratory
526 coronaviruses. *J Virol* **74**, 8913-8921 (2000).
- 527 12. Dube, M., *et al.* Axonal Transport Enables Neuron-to-Neuron Propagation of Human
528 Coronavirus OC43. *J Virol* **92** (2018).
- 529 13. Cheng, Q., Yang, Y. & Gao, J. Infectivity of human coronavirus in the brain. *EBioMedicine*
530 **56**, 102799 (2020).
- 531 14. Kumari, P., *et al.* Neuroinvasion and Encephalitis Following Intranasal Inoculation of
532 SARS-CoV-2 in K18-hACE2 Mice. *Viruses* **13** (2021).
- 533 15. Golden, J.W., *et al.* Human angiotensin-converting enzyme 2 transgenic mice infected
534 with SARS-CoV-2 develop severe and fatal respiratory disease. *JCI Insight* **5** (2020).
- 535 16. Zheng, J., *et al.* COVID-19 treatments and pathogenesis including anosmia in K18-hACE2
536 mice. *Nature* **589**, 603-607 (2021).
- 537 17. Ding, H., *et al.* Neurologic manifestations of nonhospitalized patients with COVID-19 in
538 Wuhan, China. *MedComm* (2020) (2020).
- 539 18. Oladunni, F.S., *et al.* Lethality of SARS-CoV-2 infection in K18 human angiotensin-
540 converting enzyme 2 transgenic mice. *Nat Commun* **11**, 6122 (2020).
- 541 19. Johnson, B.A., *et al.* Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis.
542 *Nature* **591**, 293-299 (2021).
- 543 20. Winkler, E.S., *et al.* SARS-CoV-2 infection of human ACE2-transgenic mice causes
544 severe lung inflammation and impaired function. *Nat Immunol* **21**, 1327-1335 (2020).

- 545 21. Rathnasinghe, R., *et al.* Comparison of transgenic and adenovirus hACE2 mouse models
546 for SARS-CoV-2 infection. *Emerg Microbes Infect* **9**, 2433-2445 (2020).
- 547 22. Yinda, C.K., *et al.* K18-hACE2 mice develop respiratory disease resembling severe
548 COVID-19. *PLoS Pathog* **17**, e1009195 (2021).
- 549 23. Moyano, A.J., Mejia Torres, S. & Espinosa, J. Vagus nerve neuropathy related to SARS
550 COV-2 infection. *IDCases* **26**, e01242 (2021).
- 551 24. Daly, J.L., *et al.* Neuropilin-1 is a host factor for SARS-CoV-2 infection. *Science* **370**, 861-
552 865 (2020).
- 553 25. Cantuti-Castelvetri, L., *et al.* Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity.
554 *Science* **370**, 856-860 (2020).
- 555 26. Moutal, A., *et al.* SARS-CoV-2 spike protein co-opts VEGF-A/neuropilin-1 receptor
556 signaling to induce analgesia. *Pain* **162**, 243-252 (2021).
- 557 27. Pellegrini, L., *et al.* SARS-CoV-2 Infects the Brain Choroid Plexus and Disrupts the Blood-
558 CSF Barrier in Human Brain Organoids. *Cell Stem Cell* **27**, 951-961 e955 (2020).
- 559 28. Jacob, F., *et al.* Human Pluripotent Stem Cell-Derived Neural Cells and Brain Organoids
560 Reveal SARS-CoV-2 Neurotropism Predominates in Choroid Plexus Epithelium. *Cell Stem Cell*
561 **27**, 937-950 e939 (2020).
- 562 29. Rhea, E.M., *et al.* The S1 protein of SARS-CoV-2 crosses the blood-brain barrier in mice.
563 *Nat Neurosci* **24**, 368-378 (2021).
- 564 30. Buzhdygan, T.P., *et al.* The SARS-CoV-2 spike protein alters barrier function in 2D static
565 and 3D microfluidic in-vitro models of the human blood-brain barrier. *Neurobiol Dis* **146**, 105131
566 (2020).
- 567 31. Meinhardt, J., *et al.* Olfactory transmucosal SARS-CoV-2 invasion as a port of central
568 nervous system entry in individuals with COVID-19. *Nat Neurosci* **24**, 168-175 (2021).
- 569 32. von Weyhern, C.H., Kaufmann, I., Neff, F. & Kremer, M. Early evidence of pronounced
570 brain involvement in fatal COVID-19 outcomes. *Lancet* **395**, e109 (2020).
- 571 33. Tutuncu, E.E., Ozgur, D. & Karamese, M. Saliva samples for detection of SARS-CoV-2 in
572 mildly symptomatic and asymptomatic patients. *J Med Virol* **93**, 2932-2937 (2021).
- 573 34. Ota, K., *et al.* Detection of SARS-CoV-2 using qRT-PCR in saliva obtained from
574 asymptomatic or mild COVID-19 patients, comparative analysis with matched nasopharyngeal
575 samples. *PLoS One* **16**, e0252964 (2021).
- 576 35. Huang, N., *et al.* SARS-CoV-2 infection of the oral cavity and saliva. *Nat Med* **27**, 892-903
577 (2021).
- 578 36. Song, J., *et al.* Systematic analysis of ACE2 and TMPRSS2 expression in salivary glands
579 reveals underlying transmission mechanism caused by SARS-CoV-2. *J Med Virol* **92**, 2556-2566
580 (2020).
- 581 37. Shiers, S., *et al.* ACE2 and SCARF expression in human dorsal root ganglion nociceptors:
582 implications for SARS-CoV-2 virus neurological effects. *Pain* **161**, 2494-2501 (2020).
- 583 38. Garg, R.K., Paliwal, V.K. & Gupta, A. Spinal cord involvement in COVID-19: A review. *J*
584 *Spinal Cord Med*, 1-15 (2021).
- 585 39. Bulfamante, G., *et al.* First ultrastructural autoptic findings of SARS -Cov-2 in olfactory
586 pathways and brainstem. *Minerva Anesthesiol* **86**, 678-679 (2020).
- 587 40. Song, E., *et al.* Neuroinvasion of SARS-CoV-2 in human and mouse brain. *J Exp Med* **218**
588 (2021).
- 589 41. Chepurinov, A.A., Dadaeva, A.A., Malkova, E.M., Kolesnikov, S.I. & Sandakhchiev, L.S.
590 Symptoms of infection caused by SARS coronavirus in laboratory mice and guinea pigs. *Dokl Biol*
591 *Sci* **397**, 310-313 (2004).
- 592 42. Liang, L., *et al.* Pathology of guinea pigs experimentally infected with a novel reovirus and
593 coronavirus isolated from SARS patients. *DNA Cell Biol* **24**, 485-490 (2005).

- 594 43. Li, K.K., *et al.* Characterisation of animal angiotensin-converting enzyme 2 receptors and
595 use of pseudotyped virus to correlate receptor binding with susceptibility of SARS-CoV infection.
596 *Hong Kong Med J* **18 Suppl 3**, 35-38 (2012).
597 44. Brooke, G.N. & Prischi, F. Structural and functional modelling of SARS-CoV-2 entry in
598 animal models. *Sci Rep* **10**, 15917 (2020).
599 45. Conceicao, C., *et al.* The SARS-CoV-2 Spike protein has a broad tropism for mammalian
600 ACE2 proteins. *PLoS Biol* **18**, e3001016 (2020).
601

602 **Methods**

603 **Ethics statement.** This study was approved by the Virginia Polytechnic Institute & State
604 University Institutional Animal Care and Use Committee (Protocol # 20-228, approved
605 02/01/2021). This study was carried out according to the US Department of Agriculture's Animal
606 Welfare Act and the Public Health Service's Policy on Humane Care and Use of Laboratory
607 Animals.

608 **Cells and virus.** SARS-CoV-2 isolate USA-WA1/2020 (NR-52281; BEI) was passaged twice
609 using Vero E6 cells (CRL-1586, ATCC) to produce viral stock for all infections. USA-WA1/2020
610 was recovered from an oropharyngeal swab taken from a 35-year-old male in Washington state
611 in January 2020 who was diagnosed with COVID-19 after returning from visiting family in Wuhan,
612 China. Viral stocks were titrated in duplicate using a standard plaque assay on Vero E6 cells with
613 agarose overlay⁴⁶. Vero E6 cells were maintained following standard cell culture protocols.

614 **Mouse infections.** Eight to ten-week-old male and female B6.Cg-Tg(K18-hACE2)2PrImn/J mice
615 (Stock # 034860; Jackson Laboratory; n=12, 2 groups of 6 mice), and their wild-type C57BL/6J
616 counterparts (n=12, 2 groups of 6 mice) were inoculated intranasally with SARS-CoV-2 isolate
617 USA-WA1/2020 (Extended Data Fig 1a). Inoculations were carried out under ketamine/xylazine
618 anesthesia in the on campus ABSL-3 facility after a one-day acclimation period. Mice received 20
619 μ L of either 10^3 PFU (2 groups per mouse type) or 10^5 PFU (2 groups per mouse type) of SARS-
620 CoV-2 in 1X PBS. The inoculum was split between the nares for each mouse. Uninfected K18-
621 hACE2 control mice (n=2) and C57BL/6J wild-type control mice (n=2) were housed in a separate
622 on campus ABSL-1 facility. Aliquots of the inocula and viral stock were saved for back titration
623 using plaque assay for infectious viral titer and RT-qPCR for RNA copy number. All mice were
624 genotyped following Jackson Laboratory protocol # 38170 V2. Mice were assessed daily for signs
625 of disease and changes in weight and temperature. Mice from each group (K18-hACE2, WT) and
626 inoculum dose (10^5 PFU, 10^3 PFU) were euthanized 3 days post infection (dpi) (n=3) and at 6 dpi
627 (n=3). Tissues collected included blood, CNS tissues (olfactory bulb, hippocampus, brainstem,
628 cerebellum, cortex, spinal cord), PNS tissues (autonomic ganglia: superior cervical ganglia-SCG;
629 sensory ganglia: dorsal root ganglia-DRG, trigeminal ganglia-TG), viscera (lung, spleen, liver,
630 kidney, pancreas). Half of the tissues were collected in TRI Reagent for RNA extraction and RT-
631 qPCR and the other half collected in 10% formalin for immunostaining. Brains were split into
632 hemispheres maintaining attachment with the olfactory bulb. One hemisphere was fixed in
633 formalin for immunostaining and the other dissected out into individual brain regions with each
634 placed in TRI Reagent for RT-qPCR. This experiment was repeated as above for reproducibility.
635 Tissue collection from the second experiment was split between TRI Reagent for RT-qPCR as
636 above or flash frozen on dry ice for plaque assay. Blood, spleen, liver, kidney, and pancreas
637 samples from the initial infection study were assessed via RT-qPCR to assess for disseminated
638 infection at 3- and 6- dpi. As these tissues were not the main focus of the investigations, they

639 were not assessed in the replicate study at 3- and 6- dpi. Lungs from the initial and replicate
640 infection studies were assessed to verify infection at 3- and 6- dpi.

641 To assess viral spread through nervous tissues at earlier timepoints during infection, and to
642 determine the role, if any that viremia plays verses direct neuronal invasion, K18-hACE2 (n=10)
643 and WT mice (n=10) were infected with 10^5 PFU SARS-CoV-2 as described above and were
644 euthanized 1- and 2-dpi (n=5 of each group/day). Blood, PNS tissues, CNS tissues (with addition
645 of pituitary gland), and salivary glands were collected as described above for RT-qPCR, plaque
646 assays, and immunostaining.

647 **Guinea pig infections.** After a two-day acclimation period, three-week-old female Hartley guinea
648 pigs (Hilltop Lab Animals) were infected with either 10^3 PFU (n=12) or 10^5 PFU (n=12) of SARS-
649 CoV-2 as described for K18-hACE2 mice in the ABSL-3 facility (Extended Data Fig 1a.).
650 Uninfected controls (n=2) were housed in the ABSL-2 facility. Guinea pigs were monitored daily
651 as described for mice. Tissue types collected, methods of collection, and downstream assays
652 were the same as described for the mice.

653 **RNA extraction and SARS-CoV-2 specific RT-qPCR.** RNA was extracted and RT-qPCR
654 performed as previously described⁴⁷. Briefly, tissues were homogenized in 200 μ L TRI Reagent
655 (Fisher Scientific) using a handheld tissue homogenizer with sterile pestles (Cole-Parmer). RNA
656 was extracted using a standard guanidinium thiocyanate-phenol-chloroform extraction. RNA
657 purity and quantity was assessed using a NanoDrop 2000 spectrophotometer (ThermoFisher).
658 SARS-CoV-2 RT-qPCR reactions (10 μ L) using the iTaq Universal Probe One-Step Kit (BioRad)
659 and SARS-CoV-2 N1 primers/probe mix (Stock# 10006713; Integrated DNA Technologies) were
660 run on a ViiA 7 Real-Time PCR system (Applied Biosystems) as described in the instructions for
661 use of the CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR assay. Cycle
662 conditions were as follows: Standard setting; 50°C (10 min, 1 cycle), 95°C (2 min, 1 cycle), 95°C
663 then 55°C (30s then 3 s, 45 cycles). Results were reported as genome copy number per 200 ng
664 total RNA.

665 **Immunofluorescence.** Tissues were prepared for immunostaining as previously described⁴⁸.
666 Briefly, viscera were fixed in 10% formalin and ganglia were fixed in 4% paraformaldehyde
667 overnight, moved to 30% sucrose overnight, and subsequently embedded in optimal cutting
668 temperature media (ThermoFisher). A Leica CM3050-S cryostat (Leica Biosystems) was used to
669 prepare 7 μ m sections from each tissue block. Slides were rinsed in 1X PBS then blocked in 3%
670 normal donkey serum, 0.1% Triton-100X, and 1X PBS for 30 min at room temperature. SARS-
671 CoV-2 N protein was visualized using an Alexa Fluor® 488 conjugated rabbit monoclonal anti-
672 SARS-CoV-2 nucleocapsid antibody at a 1:1000 concentration (NBP2-90988AF488; Novus
673 Biologicals). hACE2 was visualized using an Alexa Fluor® 594 conjugated mouse monoclonal
674 anti-ACE2 antibody at a 1:1000 concentration (sc-390851 AF594; Santa Cruz Biotechnology).
675 NeuN was visualized using an Alexa Fluor® 647 conjugated rabbit monoclonal anti-NeuN
676 antibody at a 1:1000 concentration (ab190565; Abcam). α -d-galactose carbohydrate residues on
677 sensory neurons was visualized using the *Bandeiraea simplicifolia* isolectin B4 (IB4) conjugated
678 to rhodamine at a 1:250 concentration (RL-1102; Vector Laboratories). Tyrosine hydroxylase was
679 visualized using an Alexa Fluor® 594 conjugated mouse monoclonal anti-TH antibody at a 1:500
680 concentration (818004; Biolegend). Glutamine synthetase was visualized using a mouse
681 monoclonal anti-GS antibody at a 1:100 concentration (MA5-27750; Invitrogen) followed by an
682 Alexa Fluor® 594 conjugated goat anti-mouse monoclonal antibody at a 1:1000 concentration
(A11005; Invitrogen). Neuropilin-1 was visualized using a goat polyclonal anti-NRP1 antibody at

684 a 15 µg/mL concentration (AF566; R&D Systems) followed by an Alexa Fluor® 647 conjugated
685 donkey anti-goat monoclonal antibody at a 1:1000 concentration (ab150135; Abcam). Nuclei were
686 visualized with 4',6-diamidino-2-phenylindole (DAPI) in SlowFade Diamond antifade mounting
687 medium (ThermoFisher). Primary antibodies were incubated with tissues overnight at 4°C in 1%
688 normal donkey serum, 0.1% Triton-100X, and 1X PBS. Secondary antibodies were incubated with
689 tissues for 1 hour at room temperature.

690 **Confocal microscopy and image analysis.** Imaging was performed using a Leica SP8 scanning
691 confocal microscope. Sections of ganglia, brain, and spinal cord were imaged with identical laser
692 power and gain settings within tissue type to account for background immunofluorescence. Cells
693 from in vitro studies were imaged with varying laser power and/or gain due to the wide range of
694 immunofluorescence observed within given experiments. Images were imported into ImageJ and
695 contrast and brightness was adjusted identically across all images within tissue types. 3D models
696 were made using ImageJ and SyGlass VR imaging software.

697 **Plaque assays.** Flash frozen tissues were homogenized in Dulbecco's Modified Eagle Medium
698 (DMEM; Fisher Scientific) in bead tubes using a TissueLyser II (Qiagen) for 45 s sessions for
699 three sessions. Ganglia were homogenized in 0.5 mL DMEM due to size. Brain regions and spinal
700 cord segments were homogenized in 1.0 mL of DMEM. The undiluted tissue homogenate as well
701 as a ten-fold dilution of homogenate was inoculated in duplicate onto confluent monolayers of
702 Vero E6 cells in 24-well plates. After 1 h of adsorption, the inoculum was removed, a 0.5%
703 agarose overlay added (DMEM with 8% fetal bovine serum, 1% penicillin/streptomycin, molecular
704 grade agarose), and plates were returned to the incubator for 48 h at 37°C with 5% CO₂. Plates
705 were then fixed with 10% formaldehyde, the agarose overlay removed, and stained with plaque
706 dye. Infectious viral titer is reported as plaque forming units per mL (PFU/mL) of tissue
707 homogenate.

708 **Primary neuronal culture.** Neurons from sensory ganglia (TG, DRG) and autonomic ganglia
709 (SCG) were collected from mature mice and cultured as previously described⁴⁹⁻⁵¹. Briefly, ganglia
710 were harvested from 8–10-week-old K18-hACE2 and WT mice and enzymatically digested with
711 a sequential incubation of papain (Worthington) and collagenase/dispase (Sigma-Aldrich)
712 followed by washes in Neurobasal A (Invitrogen) after each digestion. Ganglia were triturated into
713 single cell suspensions via pipette and further washed. SCGs and DRGs were brought to volume
714 in “complete media” containing Neurobasal A with 2% B27 (Invitrogen), 1% penicillin-streptomycin
715 (Thermo Fisher), L-glutamine (Thermo Fisher), fluorodeoxyuridine (Sigma-Aldrich), and
716 neurotrophic factors (PeproTech). Neurons were plated at a concentration of 3,000 neurons/well
717 in Matrigel coated Lab-Tek II 8-well chamber slides or 24-well plates (Thermo Fisher). TGs were
718 collected after separation from debris via density gradient centrifugation using OptiPrep (Sigma-
719 Aldrich) with subsequent washes in Neurobasal A. TGs were plated as described for SCGs and
720 DRGs.

721 **Neuronal infection.** Neurons from K18-hACE2 and WT mice were inoculated with SARS-CoV-2
722 isolate USA-WA1/2020 at 30 MOI in 100 µL Neurobasal A (Invitrogen) for 8-well chamber slides
723 and 200 µL for 24-well plates for 1 h. Following the 1 h adsorption the inoculum was removed,
724 fresh complete media was added (without fluorodeoxyuridine), and neurons were incubated at
725 37°C with 5% CO₂. Aliquots of the inocula and viral stock were saved for back titration using
726 plaque and RT-qPCR.

727 **Quantification of burden of neuronal infection in autonomic and sensory ganglia.** To
728 quantify the number of autonomic (SCG) and sensory (DRG) neurons infected per ganglia, 8-well
729 chamber slides were fixed with paraformaldehyde at 1-, 2-, and 3-dpi and stained as described
730 above for the detection of SARS-CoV-2 nucleocapsid. The number of infected neurons from each
731 ganglion were counted for each day, averaged, and reported as the percentage of infected
732 neurons per 500 neurons counted. DRG neurons were chosen as the representative sensory
733 neuron as they had the more dynamic replication kinetics with successive rounds of replication.

734 **Detection of SARS-CoV-2 assembly and release from neurons.** To determine if neurons from
735 K18-hACE2 and WT mice are permissive to infection and release of infectious virus, neurons
736 were incubated for up to 5 dpi (depending on availability of neurons from the specific ganglia) with
737 daily sampling. To determine the amount of virus bound to neurons vs that left unbound
738 immediately following incubation with the inoculum, the inoculum and neurons were collected
739 separately and constitute the 0 dpi sample. Daily, media and neurons were collected separately
740 in duplicate (TGs, DRGs) or singularly (SCGs) in 500 μ L of LS-TRI Reagent (Fisher Scientific) for
741 RNA extraction and viral genome copy number quantitation via RT-qPCR as described above.
742 Samples were stored at 4°C until processing. For quantification of viral titer in neurons vs that
743 released into the media, neurons and media were collected separately in duplicate (TGs, DRGs)
744 or singularly (SCGs). To correct for evaporation of media throughout the time course the final
745 volume of collected media was brought up 500 μ L by adding DMEM prior to plaque assay.
746 Neurons were collected in 500 μ L DMEM after scraping with a pipette tip. Samples were
747 immediately stored at -80°C until processing for plaque assay as described above. Following
748 collection of the media but prior to collection of the neurons in TRI reagent or DMEM, the neurons
749 were gently washed with 500 μ L DMEM which was then discarded, to remove any residual media
750 containing RNA or virus. A similar rinse was performed immediately after the 1 h inoculation to
751 remove any residual inoculum.

752 **Inhibition of SARS-CoV-2 infection by neuropilin-1 blockade in primary sensory neuronal**
753 **culture.** Primary neuronal cultures of DRGs from K18-hACE2 and WT mice were established as
754 described above. Neurons were pretreated with 100 μ M of the NRP-1 antagonist EG00229 (6986;
755 Tocris) dissolved in DMSO prior to infection as described for Caco-2 cells²⁴. EG00229 putatively
756 blocks binding between the carboxyl-terminal sequence of SARS-CoV-2 S1 which has a C-end
757 rule (CendR) motif and the extracellular b1b2 CendR binding pocket of NRP-1, which has been
758 suggested as an alternative co-receptor for SARS-CoV-2 in non-neuronal cells²⁴⁻²⁶. Neurons were
759 infected as described above. To determine if NRP-1 blockade impacted SARS-CoV-2 entry and
760 therefore subsequent replication in neurons, neurons and media were collected together in LS-
761 TRI Reagent (Fisher Scientific). RNA was isolated and virus replication assessed via RT-qPCR
762 as described above. Samples were collected at initial peak replication times as determined
763 through our previous neuronal growth kinetics studies (DRG; 3 dpi) to assess if these peaks
764 were blunted or completely inhibited. Infected neurons from K18-hACE2 and WT mice not treated
765 with EG00229 but with an equivalent amount of DMSO, the solvent for EG00229, served as
766 controls.

767 **Statistics and reproducibility.** Sample sizes were not statistically calculated as they are similar
768 to sample sizes used in other SARS-CoV-2 studies using K18-hACE2 mice^{14, 15, 18, 20}. Animals
769 were randomly assigned to either inoculum group or control group ensuring the groups were age-
770 matched. Measurements were taken from distinct samples. RT-qPCR and plaque assays were
771 performed in duplicate for each sample when assessing both *in-vivo* and *ex-vivo* infections. RT-

772 qPCR results that fell below the lower limit for the standard curve (8 copies) after normalization
773 were reported as 0 for inclusion in analysis, no data were excluded. Neuronal infection studies,
774 both immunostaining as well as plaque assay and RT-qPCR studies, were repeated in three
775 separate experiments, with duplicate samples for each ganglion and timepoint in K18-hACE2 and
776 in duplicate in WT mice. Neuropilin-1 inhibition studies were repeated twice, with duplicate
777 samples for each timepoint in K18-hACE2 and WT mice. Mouse infection studies were repeated
778 as described. Guinea pig infection studies were conducted as described. All statistical analyses
779 were performed in JMP Pro 16 (SAS Institute) and confirmed in GraphPad Prism version 8 during
780 figure creation. For statistical analysis, significance was set at $p < 0.05$, calculated as two-tailed.
781 RT-qPCR data was log transformed before analysis to correct for normality of distribution. RT-
782 qPCR data was analyzed using a multifactorial ANOVA. If significance was found, pairwise
783 analysis was performed using Tukey's honestly significant difference (HSD) post hoc test. Inhibitor
784 studies were analyzed using unpaired two-tailed t-tests.

785 **Reporting summary.** Further information on research design is available in the Nature Research
786 Reporting Summary linked to this article.

787 **Data availability**

788 Data generated during this study and referenced in this manuscript are available from the
789 corresponding author upon reasonable request.

790 **Methods references**

791 46. Harcourt, J., *et al.* Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with
792 Coronavirus Disease, United States. *Emerg Infect Dis* **26**, 1266-1273 (2020).

793 47. Jia, M., Taylor, T.M., Senger, S.M., Ovissipour, R. & Bertke, A.S. SARS-CoV-2 Remains
794 Infectious on Refrigerated Deli Food, Meats, and Fresh Produce for up to 21 Days. *Foods* **11**
795 (2022).

796 48. Joyce, J.D., *et al.* Assessment of Two Novel Live-Attenuated Vaccine Candidates for
797 Herpes Simplex Virus 2 (HSV-2) in Guinea Pigs. *Vaccines (Basel)* **9** (2021).

798 49. Bertke, A.S., *et al.* A5-positive primary sensory neurons are nonpermissive for productive
799 infection with herpes simplex virus 1 in vitro. *J Virol* **85**, 6669-6677 (2011).

800 50. Powell-Doherty, R.D., Abbott, A.R.N., Nelson, L.A. & Bertke, A.S. Amyloid-beta and p-Tau
801 Anti-Threat Response to Herpes Simplex Virus 1 Infection in Primary Adult Murine Hippocampal
802 Neurons. *J Virol* **94** (2020).

803 51. Bertke, A.S., *et al.* LAT region factors mediating differential neuronal tropism of HSV-1
804 and HSV-2 do not act in trans. *PLoS One* **7**, e53281 (2012).

805 **Acknowledgments**

806 This research was funded by internal COVID-19 rapid response seed funding from the Fralin Life
807 Sciences Institute at Virginia Tech. The following reagent was deposited by the Centers for
808 Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH: SARS-
809 Related Coronavirus 2, Isolate USA-WA1/2020, NR-52281. Special thanks to Jonathan Auguste,
810 Will Stone, and Addie Hayes for various forms of assistance.

811 **Author contributions**


812 Conceptualization, JDJ, ASB; methodology, JDJ, CKT, ASB; validation, JDJ, CKT, ASB; formal
813 analysis, JDJ, GAM, EH, CKT, ASB; investigation, JDJ, GAM, PG, EH, CKT, ASB; resources,
814 CKT, ASB; data curation, JDJ, CKT, ASB; writing—original draft preparation, JDJ; writing—review
815 and editing, JDJ, CKT, ASB; visualization, JDJ, CKT, ASB; supervision, CKT, ASB; project

816 administration, ASB; funding acquisition, ASB. All authors have read and agreed to the published
817 version of the manuscript.


818 **Competing interests**

819 The authors declare no competing interests.

820




TG: Trigeminal ganglia; SCG: Superior cervical ganglia; DRG: Dorsal root ganglia



821


822 **Extended Data Fig 1. | Experimental approach and clinical data for hACE2 mice, WT mice, and**
 823 **guinea pigs.** **a**, Graphical abstract outlining the experimental approach used in both mouse and guinea pig
 824 infections highlighting intranasal infection of groups with either 3 log PFU or 5 log PFU SARS-CoV-2, clinical
 825 evaluation (temperature, weight, survival), collection of tissues from half of each group at 3- and 6-dpi, and
 826 downstream analysis for SARS-CoV-2 RNA copies (RT-qPCR), virus and host antigen (immunostaining),
 827 and infectious virus (plaque assay). **b** Clinical data by inoculum group for mice and guinea pigs including
 828 weight, temperature, and survival. Weight (grams) for each animal was recorded daily. Weight is reported
 829 as the mean percentage increase/decrease for each inoculum group relative to the mean starting weight
 830 for that group. The only group to exhibit notable weight loss was the hACE2 mice inoculated with 5 log
 831 PFU, which began to lose weight after 3 dpi. Both inoculum groups of guinea pigs gained weight but at a
 832 slower rate than uninfected controls. Temperature (°C) for each animal was recorded daily. Temperature is
 833 reported as the mean percentage increase/decrease for each inoculum group relative to the mean starting
 834 temperature for that group. While transient increases in temperature in the 5 log PFU inoculum groups in
 835 both mice and guinea pigs were noted, they were not significant. Kaplan-Meier survival plots were created
 836 for each inoculum group. The only group to have mortality was the hACE2 mice inoculated with 5 log PFU.
 837 Mortality was noted at 6 dpi (14%, n= 2 of 14).



838


839 **Extended Data Fig 2. | SARS-CoV-2 genome copy numbers in blood and viscera in hACE2 and WT**
840 **mice. a**, SARS-CoV-2 RNA was detected in lungs of hACE2 and WT mice in both inocula groups at both
841 timepoints, which decreased over time. While differences were detected in the lungs ($F(7, 41) = 2.745$, $p =$
842 0.0197) none were between relevant groups. **b**, Low concentrations of SARS-CoV-2 RNA were detected
843 in the blood of hACE2 in both inoculum groups at 3 dpi and both hACE2 and WT mice in both inoculum
844 groups at 6 dpi. A significant difference ($F(7, 40) = 3.417$, $P = <0.006$) was detected in the WT group
845 inoculated with 10^3 PFU assessed at 3- vs 6-dpi ($p = 0.0321$). Low concentrations of SARS-CoV-2 RNA
846 were also detected in the spleen **c**, liver **d**, kidney **e**, and pancreas **f**, of both inoculum groups in hACE2
847 and WT mice, mostly appearing at 6 dpi. Data are the mean \pm s.e.m. Log transformed RNA genome copy
848 numbers were statistically compared by three-way ANOVA (independent variables: inocula, days post
849 infection, genotype). Pairwise comparisons were conducted using Tukey's HSD post hoc tests. * $p < 0.05$,
850 ** $p < 0.01$, *** $p < 0.001$.

851





852

853 **Extended Data Fig 3. | Immunofluorescence for SARS-N protein and NeuN in sections of brain and**
854 **lung from infected guinea pigs.** All images were acquired using a Leica SP8 confocal microscope, using
855 identical image acquisition and ImageJ settings used in Fig 4. No SARS-N was detectable in brains or lungs
856 at 6 dpi.




857

858 **Extended Data Fig 4. | Immunofluorescence for SARS-N protein and NeuN in peripheral ganglia from**
859 **hACE2 mice.** All images were acquired using a Leica SP8 confocal microscope, using identical image
860 acquisition settings (laser power and gain) across all sections shown. All images were colorized, z-
861 projected, and prepared using identical contrast and brightness parameters in ImageJ. SARS-N is present
862 in neurons in the DRG, TG and SCG in infected mice. Minimal background immunofluorescence is
863 observed in sections from uninfected mice. Of note is substantial vacuolization and loss of NeuN
864 immunofluorescence in the infected SCG.



865

866 **Extended Data Fig 5. | Example images of immunofluorescence for SARS-N protein and NeuN in**
867 **sections of spinal cords and brains taken from infected and uninfected hACE2 mice.** All images were
868 acquired using a Leica SP8 confocal microscope, using identical image acquisition settings (laser power
869 and gain) across all sections from each tissue type shown. All images were colorized, z-projected, and
870 prepared using identical contrast and brightness parameters in ImageJ. SARS-N is present in neurons in
871 the spinal cord and brains in infected mice. Minimal background immunofluorescence is observed in
872 sections from uninfected mice. Of note, SARS-N intensity was qualitatively substantially higher in the brain
873 than in the spinal cord.



874

875 **Extended Data Fig 6. | Example images of immunofluorescence for SARS-N protein in *in vitro* cells**
876 **taken from peripheral ganglia, incubated for two days, then inoculated with SARS-CoV-2.** Cells were
877 fixed 1-3 dpi and stained for SARS-N and various counterstains. All images were acquired using a Leica
878 SP8 confocal microscope. Because of substantial variability in intensity of SARS-N immunofluorescence,
879 laser power and gain were adjusted in order to highlight features of each cell. Day 2 DRG is a montage
880 image to show SARS-N detected throughout the neurites of one infected neuron; only DAPI is shown.
881 SARS-N is present in neurons in the SCG, TG, and DRG in infected mice. TH = tyrosine hydroxylase, IB4
882 = Isolectin-IB4, GS = glutamine synthetase, SARS-N = SARS-CoV-2 nucleocapsid, DAPI = 4',6-diamidino-
883 2-phenylindole. Scale bar = 20 μ m

884